Trends in Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: 35(8), P. 687 - 696
Published: April 17, 2024
Language: Английский
Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 22(5), P. 291 - 308
Published: Dec. 18, 2023
Language: Английский
Citations
50
Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117302 - 117302
Published: Aug. 19, 2024
Inflammatory bowel disease (IBD), including Crohn's and ulcerative colitis, is a complex disorder with an unknown cause. However, the dysbiosis of gut microbiome has been found to play role in IBD etiology, exacerbated immune responses defective intestinal barrier integrity. The can also be potential biomarker for several diseases, IBD. Currently, conventional treatments targeting pro-inflammatory cytokines pathways IBD-associated do not yield effective results. Other therapies that directly target dysbiotic outcomes are emerging. We review health its as diagnostic, prognostic, therapeutic This explores emerging advancements microbiome-associated alterations IBD, such nanoparticle or encapsulation delivery, fecal microbiota transplantation, nutritional therapies, microbiome/probiotic engineering, phage therapy, mesenchymal stem cells (MSCs), proteins, herbal formulas.
Language: Английский
Citations
16
Expert Review of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 6, 2025
The gut microbiota has a complex relationship with the human host and is key to maintaining health. Disruption of healthy diverse microbial milieu plays an important role in pathogenesis several diseases including
Language: Английский
Citations
2
Infection and Drug Resistance, Journal Year: 2024, Volume and Issue: Volume 17, P. 1107 - 1119
Published: March 1, 2024
Abstract: Infections with drug-resistant bacteria have become one of the greatest public health challenges, and K. pneumoniae is among top six bacteria. often causes nosocomial infections, leading to illnesses such as pneumonia, liver abscesses, soft tissue urinary tract bacteremia, in some cases death. As pathogen continues evolve its multidrug resistance increases, poses a direct threat humans. Drug may occur due formation biofilms, efflux pumps, production β-lactamases. In many cases, further enhanced by enzymatic modification loss porins. has led decline effectiveness conventional therapies against this pathogen. Therefore, there an urgent need accelerate development new antibiotics explore therapeutic approaches antimicrobial peptides, phages, traditional Chinese medicine, immunotherapy, Antimicrobial nanoparticle technology, antisense oligonucleotides gene editing technologies. review, we discuss mechanisms drug compare several potential strategies overcome treatment infections. Keywords: Klebsiella , antibiotic mechanisms,
Language: Английский
Citations
14
Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 21(8), P. 556 - 571
Published: June 3, 2024
Language: Английский
Citations
14
The Lancet Microbe, Journal Year: 2024, Volume and Issue: 5(5), P. e489 - e499
Published: March 4, 2024
Colonisation by bacterial pathogens typically precedes invasive infection and seeds transmission. Thus, effective decolonisation strategies are urgently needed. The literature reports attempts to use phages for decolonisation. To assess the in-vivo efficacy safety of decolonisation, we performed a systematic review identifying relevant studies We searched PubMed, Embase (Ovid), MEDLINE Web Science, Cochrane Library identify articles published between Jan 1, 1990, May 12, 2023, without language restrictions. included that assessed phage in humans or vertebrate animal models. This is registered with PROSPERO, CRD42023457637. identified 6694 articles, which 56 (51 five clinical reports) met predetermined selection criteria were final analysis. gastrointestinal tract (n=49, 88%) was most studied colonisation site, other sites central venous catheters, lung, nose, skin, urinary tract. Of studies, load at site reported decrease significantly 45 (80%) but only described eradication target bacteria. 15 No obvious adverse events both short-term long-term observation period. Given increasing life-threatening risks posed bacteria difficult treat, could be an alternative option although further optimisation required before their application meet needs.
Language: Английский
Citations
10
Microbiological Research, Journal Year: 2025, Volume and Issue: unknown, P. 128083 - 128083
Published: Jan. 1, 2025
Language: Английский
Citations
1
JHEP Reports, Journal Year: 2023, Volume and Issue: 5(12), P. 100909 - 100909
Published: Sept. 23, 2023
Phage therapy has been overshadowed by antibiotics for decades. However, it is being revisited as a powerful approach against antimicrobial-resistant bacteria. As bacterial microbiota have mechanistically linked to gastrointestinal and liver diseases, precise editing of the gut via selective bactericidal action phages prompted renewed interest in phage therapy. In this review, we summarise basic virological properties latest findings on composition intestinal phageome changes associated with diseases. We also review preclinical clinical studies assessing treatment well future prospects challenges.
Language: Английский
Citations
19
Current Opinion in Gastroenterology, Journal Year: 2024, Volume and Issue: 40(3), P. 134 - 142
Published: Feb. 16, 2024
Purpose of review The intestinal microbiome and the gut-liver axis play a major role in health disease. human gut harbors trillions microbes disruption homeostasis can contribute to liver In this review, progress field within last 3 years is summarized, focusing on metabolic dysfunction-associated steatotic disease (MASLD), alcohol-associated (ALD), autoimmune (AILD), hepatocellular carcinoma (HCC). Recent findings Changes fecal virome fungal mycobiome have been described patients with various diseases. Several microbial derived metabolites including endogenous ethanol produced by bacteria, mechanistically linked such as MASLD. Virulence factors encoded bacteria ALD, AILD HCC. Novel therapeutic approaches focused phages, pre- postbiotics successfully used preclinical models. Fecal microbiota transplantation has effective attenuating Probiotics are safe hepatitis improve alcohol addiction. Summary gut–liver plays key pathophysiology Understanding help develop precise centered therapies.
Language: Английский
Citations
7
Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2372 - 2372
Published: July 22, 2024
Hepatobiliary malignancies, which include hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), are the sixth most common cancers third leading cause of cancer-related death worldwide. Hepatic carcinogenesis is highly stimulated by chronic inflammation, defined as fibrosis deposition, an aberrant imbalance between liver necrosis nodular regeneration. In this context, gut-liver axis gut microbiota have demonstrated a critical role in pathogenesis HCC, dysbiosis altered intestinal permeability promote bacterial translocation, to inflammation tumorigenesis through several pathways. A few data exist on or bacteria resident biliary tract CCA, some microbial metabolites, such choline bile acids, seem show association. review, we analyze impact its metabolites HCC CCA development biomarker hepatobiliary cancer risk response during anti-tumor therapy. We also discuss future application management.
Language: Английский
Citations
7